SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Opendoor Technologies, Inc. engages in the operation of buying, selling, and trading of residential properties online. The company was founded by Eric Wu on December 30, 2013, and is headquartered in Tempe, AZ.

Opendoor Technologies Inc

Opendoor Technologies is trending strongly following reports that a former US President is instructing representatives to buy $200 billion in mortgage bonds, a move expected to significantly lower mortgage rates and enhance housing affordability. The community is highly optimistic, anticipating a substantial surge in the housing market and a potential short squeeze, with many celebrating this development as a major catalyst for the company's prospects.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as its innovative Optical Interposer technology gains significant validation, notably following Marvell's acquisition of partner Celestial AI, underscoring its pivotal role in next-generation AI and data center optical interconnects. The community is buzzing about POET's patented, high-speed, and energy-efficient solutions, which are critical for scaling AI infrastructure beyond copper's limitations. Speculation is high for major upcoming orders and a substantial revenue ramp, positioning the company as a key player in the photonics sector.

Sailana Inu, the sister of legendary Saitama Inu, is bringing back the Wolfpack and OG community vibes that previously sent Saitama to a $7 billion marketcap in 2021. The power of community mixed with great leadership is what will take this project to great heights. Join the movement, join the pack, become apart of the Sailana Army . Together, we will create something that will go down in history, and something that will be talked about years from now.

Sailana Inu

Sailana Crypto is gaining significant attention as its dedicated "Wolfpack" community rallies around the recent launch of WolfSwap, a cross-chain aggregator, and eagerly anticipates a groundbreaking flagship utility. The community remains highly bullish, driven by continuous building and a vision to usher in a new era for memecoins, emphasizing decentralized growth and utility.

Federal National Mortgage Association is a government-sponsored company, which engages in the provision of liquidity for purchases of homes and financing of multifamily rental housing and refinancing existing mortgages. It operates through the Single-Family and Multifamily segments. The Single-Family segment offers liquidity to the mortgage market and increases the availability and affordability of housing for single families. The Multifamily segment includes guaranty fees on mortgages and on multifamily mortgage loans. The company was founded in 1938 and is headquartered in Washington, DC.

Federal National Mortgage Association

Federal National Mortgage Association (FNMA) is trending amidst heightened speculation about its future, fueled by recent commentary from prominent figures regarding potential government-directed mortgage bond purchases and its substantial cash reserves. The community is actively discussing these developments as signals for the long-anticipated privatization, including a potential uplisting or IPO, which could significantly impact the housing market and mortgage rates. Noted investors are also expressing bullish sentiment, further intensifying the conversation around the mortgage giant's path out of conservatorship.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending following a high-profile social media post from former President Trump, praising the company's CEO, government investment, and new sub-2nm CPU processor. This has fueled widespread community discussion around Intel's renewed technological competitiveness with its 18A process and Core Ultra Series 3 chips for AI PCs, driving optimism for a significant turnaround despite some skepticism about sustained momentum.

Rocket Cos., Inc. engages in the provision of a suite of services related to homeownership and other personal financial transactions. It operates through the following segments: Direct to Consumer and Partner Network. The Direct to Consumer segment consists of performance marketing and direct engagement through the Rocket Mortgage App. The Partner Network Segment focuses on partnerships with premier consumer-focused organizations, brokers and mortgage professionals who leverage the platform and scale to provide mortgage solutions to clients. The company was founded by Daniel Gilbert in 1985 and is headquartered in Detroit, MI.

Rocket Companies Inc - Ordinary Shares Class A

Rocket Companies is gaining significant attention following news regarding proposed governmental action aimed at boosting the housing market and lowering mortgage rates. The community anticipates a substantial refinancing and home-buying boom, viewing RKT's integrated platform and scale as perfectly positioned to capitalize on these sector-wide tailwinds. Many express strong long-term optimism, seeing potential for significant upside as the market re-rates the company amidst a normalizing mortgage cycle and its enhanced ecosystem.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

ARDX is trending as investors digest the potential impact of Fosun Pharma's Wan Ti Le being included on China's National Reimbursement Drug List and analysts anticipate target price raises due to strong IBSRELA sales. The community is weighing potential revenue from China and speculating on milestone payments, while also discussing concerns about patent infringement and generic competition. Some investors express frustration with the stock's price movement despite positive developments, awaiting a CMS resolution.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending following recent preliminary financial guidance that prompted significant community concern over DefenCath's future revenue, particularly regarding the anticipated end of TDAPA. While many investors express frustration and question management's strategy, others contend the sell-off is an overreaction, highlighting potential legislative support and recent positive real-world evidence for DefenCath's efficacy to reassure long-term value.

Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. It utilizes Artificial Intelligence to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. It offers NOCISCAN Suite, a revolutionary software suite that works with existing high field Magnetic Resonance systems and Magnetic Resonance Spectroscopy pulse sequence packages using an optimized protocol to conduct MRS exams of lumbar discs. The company was founded by James C. Peacock, David S. Bradford, and Jeffrey Lotz in 2008 and is headquartered in Broomfield, CO.

Aclarion Inc

Aclarion Inc. is attracting significant attention following its update on triple-digit growth for its AI back pain platform, robust cash position, and no debt. The community is buzzing about the extremely low float and potential for a massive short squeeze, drawing comparisons to $SMX. However, some traders voice concerns over perceived market manipulation attempting to suppress the price, despite the strong underlying fundamentals.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health (OSCR) is a major talking point as investors await a crucial legislative outcome on the extension of Affordable Care Act subsidies, which heavily impacts its marketplace business. The community is sharply divided, with bulls anticipating a short squeeze and significant upside if an extension passes, while bears highlight ongoing legislative uncertainty and recent insider selling.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$NAMS Brand new here and I’m very interested in learning more about this company. Any resident bulls I need to read up on? I wanna know what’s a good entry, future catalysts, and what’s a reasonable timeline for an exit. Also what are the possible downsides the community might be concerned with

Finlay2

StockTwits for iOS

NewAmsterdam Pharma Company NV

 Brand new here and I’m very interested in learning more about this company. Any resident bulls I need to read up on? I wanna know what’s a good entry, future catalysts, and what’s a reasonable timeline for an exit. Also what are the possible downsides the community might be concerned with

Akebia Therapeutics Inc.

Josh Matos

@LuckyGuy9 No major catalysts until summer 2026 with possible EU approval. Rights to obi licensed to Menarini in Europe but NAMS will get solid royalties (up to ~25%) and another ~billion in milestones. After that, next major catalyst is CVOT readout in Q4 2026 or Q1 2027. NAMS is waiting on this data to file for US approval.

What the price will do in that long time before catalysts, idk. Personally waiting for a buyout for an exit, which I think will come shortly after CVOT.

They will also be starting an alzheimer&#39;s trial soon. If that hits, big *if* obviously, then the sky&#39;s the limit.

Potential downsides? CVOT failing. It&#39;s a one drug company, so this would be catastrophic to the stock price. Imo, very highly likely (&gt;90%) to be a positive outcome. Can&#39;t rule out any safety issues appearing but safety so far has been phenomenal.

As for an entry price? No idea. It&#39;s already expensive, but mgmt is very bullish with 8B peak sales estimate (which would make it cheap in comparison).

Hospital.physician

Buhka Prianka

StockTwits For Android 

 No major catalysts until summer 2026 with possible EU approval. Rights to obi licensed to Menarini in Europe but NAMS will get solid royalties (up to ~25%) and another ~billion in milestones. After that, next major catalyst is CVOT readout in Q4 2026 or Q1 2027. NAMS is waiting on this data to file for US approval.

What the price will do in that long time before catalysts, idk. Personally waiting for a buyout for an exit, which I think will come shortly after CVOT.

They will also be starting an alzheimer's trial soon. If that hits, big *if* obviously, then the sky's the limit.

Potential downsides? CVOT failing. It's a one drug company, so this would be catastrophic to the stock price. Imo, very highly likely (>90%) to be a positive outcome. Can't rule out any safety issues appearing but safety so far has been phenomenal.

As for an entry price? No idea. It's already expensive, but mgmt is very bullish with 8B peak sales estimate (which would make it cheap in comparison).

Nektar Therapeutics

Novo Nordisk A/S

Cidara Therapeutics Inc

Ovid Therapeutics Inc

Terns Pharmaceuticals Inc

Tourmaline Bio Inc

Ventyx Biosciences Inc

Mason

@masonat yo thank you for your detailed response. I agree that the current price is too high due to how far out the catalysts are. 

In my experience, shorts and tutes use long periods to suppress the price and accumulate shares. I will be following this stock closely.

 yo thank you for your detailed response. I agree that the current price is too high due to how far out the catalysts are. 

In my experience, shorts and tutes use long periods to suppress the price and accumulate shares. I will be following this stock closely.